Literature DB >> 3139381

Modulation of intestinal immune reactivity by interleukin 2. Phenotypic and functional analysis of lymphokine-activated killer cells from human intestinal mucosa.

C Fiocchi1, K R Youngman, B Yen-Lieberman, R R Tubbs.   

Abstract

There is evidence indicating that interleukin 2 may be important in the regulation of intestinal immunity, as suggested by its capacity to induce nonspecific cytotoxic (lymphokine-activated killer) activity from human intestinal mucosal mononuclear cells. The present study was designed to further explore the phenotypic and functional changes induced by interleukin 2 on intestinal lymphocytes derived from inflammatory bowel disease and control tissues. Immunohistology of intestinal mucosa demonstrated few cells bearing the activation antigen recognized by anti-Tac (anti-interleukin 2 receptor) monoclonal antibody. However, when isolated lamina proprial mononuclear cells were exposed to interleukin 2 in culture, the number of Tac-positive cells increased dramatically, a phenomenon paralleled by the generation of lymphokine-activated killer cell activity. This cytotoxic function was critically dependent on the continuous availability of interleukin 2, but not on the expression of the Tac antigen, since Tac-negative cells were also cytotoxic. Depletion of natural killer cells, fractionation into T cell-enriched and -depleted cells before and after culturing with interleukin 2, and separation into Tac-positive and -negative cells after interleukin 2 activation failed to eliminate lymphokine-activated killer cell activity, suggesting that this phenomenon is mediated by phenotypically and functionally heterogeneous cell subsets. During the induction of lymphokine-activated killer cells variable amounts of interferon-gamma were produced, but these did not correlate with the degree of cytotoxicity. No differences were observed between the response to interleukin 2 by inflammatory bowel disease and control cells. Therefore, in view of its capacity to induce significant phenotypic and functional changes in different subpopulations of intestinal mucosal mononuclear cells, interleukin 2 should be regarded as an important modulator of intestinal immune reactivity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3139381     DOI: 10.1007/bf01536684

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  40 in total

1.  Gut mucosal lymphocytes in inflammatory bowel disease: isolation and preliminary functional characterization.

Authors:  C Fiocchi; J R Battisto; R G Farmer
Journal:  Dig Dis Sci       Date:  1979-09       Impact factor: 3.199

2.  "Lymphokines": non-antibody mediators of cellular immunity generated by lymphocyte activation.

Authors:  D C Dumonde; R A Wolstencroft; G S Panayi; M Matthew; J Morley; W T Howson
Journal:  Nature       Date:  1969-10-04       Impact factor: 49.962

3.  Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.

Authors:  S Rosenberg
Journal:  J Natl Cancer Inst       Date:  1985-10       Impact factor: 13.506

4.  Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody.

Authors:  D A Fox; R E Hussey; K A Fitzgerald; O Acuto; C Poole; L Palley; J F Daley; S F Schlossman; E L Reinherz
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

5.  Immunohistologic localization and immune phenotypes of lymphocytes expressing Tac antigen in human lymphoid tissues.

Authors:  T Miyawaki; S Ohzeki; N Ikuta; H Seki; K Taga; N Taniguchi
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

6.  Spontaneous production of gamma-interferon in cultures of T lymphocytes obtained from patients with Behçet's disease.

Authors:  N Fujii; T Minagawa; A Nakane; F Kato; S Ohno
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

7.  Functional studies on the precursors of human lymphokine-activated killer cells.

Authors:  J D Gray; H Y Shau; S H Golub
Journal:  Cell Immunol       Date:  1985-12       Impact factor: 4.868

8.  Human intestinal mucosal mononuclear cells exhibit lymphokine-activated killer cell activity.

Authors:  C Fiocchi; R R Tubbs; K R Youngman
Journal:  Gastroenterology       Date:  1985-03       Impact factor: 22.682

9.  Lymphokine-activated killer cells. Analysis of progenitors and effectors.

Authors:  J R Ortaldo; A Mason; R Overton
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

10.  Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2.

Authors:  N Nogueira; G Kaplan; E Levy; E N Sarno; P Kushner; A Granelli-Piperno; L Vieira; V Colomer Gould; W Levis; R Steinman
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

View more
  5 in total

Review 1.  The immunology of inflammatory bowel disease.

Authors:  J R Lowes; D P Jewell
Journal:  Springer Semin Immunopathol       Date:  1990

2.  Phenotypic and functional characterization of T-cell lines generated from colonoscopic biopsy specimens in patients with ulcerative colitis.

Authors:  K Kusugami; J Haruta; M Ieda; M Shinoda; T Ando; A Kuroiwa; K Ina; H Iokawa; A Ishihara; S Sarai
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

3.  Morphological, phenotypic and functional characteristics of a pure population of CD56+ CD16- CD3- large granular lymphocytes generated from human duodenal mucosa.

Authors:  G Pang; A Buret; R T Batey; Q Y Chen; L Couch; A Cripps; R Clancy
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

Review 4.  The ontogeny of the gut mucosal immune system and the susceptibility to infections in infants of developing countries.

Authors:  G Prindull; M Ahmad
Journal:  Eur J Pediatr       Date:  1993-10       Impact factor: 3.183

5.  Morphological alteration of gut-associated lymphoid tissue after long-term total parenteral nutrition in rats.

Authors:  S Tanaka; S Miura; H Tashiro; H Serizawa; Y Hamada; M Yoshioka; M Tsuchiya
Journal:  Cell Tissue Res       Date:  1991-10       Impact factor: 5.249

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.